Company intelligence / Profile preview

Oncimmune

Nottingham, United Kingdomoncimmune.com ↗

Ownership: Public · ONC
Employees: ~50
Development stage: Other

Overview

Oncimmune has developed and commercialized advanced immunodiagnostic platforms for the discovery and application of antibody/autoantibody biomarker signatures. Their technology enables early disease detection—especially cancer—and supports research in immuno-oncology, autoimmune disorders, and infectious diseases. The ImmunoINSIGHTS™ platform provides comprehensive immune profiling for clinical trials and drug development.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: AntibodyAutoantibody biomarker signatures
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborates with pharmaceutical companies for clinical trial immune profiling; specific partners not listed publicly

Financials

Market cap: $37.5B
Total revenue: $1.7B
Enterprise value: $33.6B

Beyond the preview

Go deeper on Oncimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncimmune.

Explore the full profile